Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer announced Thursday it has agreed to acquire UK biotech ReViral for as much as 525 million dollars including upfront and development milestones, picking…
Pfizer is paying as much as 525 million dollars upfront and in milestones to acquire ReViral, a small UK-based biotech developing oral antivirals for…
Pfizer announced on Thursday that it has agreed to acquire ReViral, a clinical-stage biopharmaceutical company focused on respiratory syncytial virus…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Pfizer agreed to acquire ReViral, a clinical-stage RSV antiviral biotech, for total consideration up to $525M including upfront and development milestones. Lead asset sisunatovir is an oral RSV fusion inhibitor with FDA Fast Track designation. Closed June 9, 2022. Note: existing DB record has data-quality issue (date 2002-07-15); this is the correct 2022 announcement. POST-CLOSE OUTCOME (reviewed 2026-06-07): The acquisition's clinical thesis failed. Pfizer discontinued sisunatovir in October 2024 for business reasons after 'ongoing challenges' in development, including a drug-drug interaction with antacids; there were no safety concerns. The adult RSV study NCT06079320 is listed as TERMINATED on ClinicalTrials.gov ('Study discontinued due to business reasons...no changes to sponsor's assessment of the risk-benefit profile'). Pediatric/infant studies were also halted. The second ReViral program (PF-07923567 / RV-299) had already been dropped in August 2023. Pfizer's RSV antiviral pipeline is now empty; its RSV strategy centers on the Abrysvo vaccine. Sources: ClinicalTrials.gov NCT06079320; FierceBiotech (2024-11-04); Endpoints News (2024-11-04).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / ReViral Ltd. (this deal) | 2022 | $525M | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Respiratory deals